HealthCap, a leading life science venture capital firm, has opened office in the newly established incubator in the Oslo Cancer Cluster Innovation Park. HealthCap also becomes a member of the Oslo Cancer Cluster.
HealthCap recognizes the emerging life sciences industry in Norway. “The strong environment created in the dedicated oncology cluster, bringing together all parts of the oncology value chain at the world renowned Radiumhospitalet, holds promise to play an important role in the development of the next generations of oncology treatments. We look forward to take part in and contribute to this important endeavor”, says Björn Odlander, managing partner of HealthCap.
HealthCap has retained Ludvik Sandnes to supervise the Norwegian operations. Ludvik Sandnes is a special advisor to HealthCap and has more than 40 years of experience from international corporate finance and asset management. He is currently the chairman of the listed Norwegian oncology company Nordic Nanovector AS.
HealthCap will host a seminar at the Oslo Cancer Cluster Innovation Park on December 9th at 12.30.
Please sign up here, the program will be published shortly.
The CEO of Oslo Cancer Cluster and Chairman of the Board of Oslo Cancer Cluster Incubator, Ketil Widerberg says “We are extremely happy to have HealthCap on board both in the Oslo Cancer Cluster and in the Incubator. HealthCap´s track record of investing in life science is impressing, and their competence and network will be valuable for further building a viable oncology industry based on excellent cancer research at Norwegian academic institutions.”
HealthCap invests in companies developing targeted therapies for rare diseases, cancer and genetic diseases, among others. HealthCap was the lead investor in the Norwegian oncology company Algeta, which was acquired by Bayer for USD 2.9 bn, and is the largest shareholder in the Norwegian oncology companies Nordic Nanovector AS and Targovax AS.
Purely focused on oncology, the Oslo Cancer Cluster Innovation Park and Incubator, will ensure that bright ideas in the lab benefit cancer patients faster than today.
For more information, please contact:
Björn Odlander, managing partner HealthCap, email: email@example.com, phone: +46 8 442 58 50
Johan Christenson, partner HealthCap, email: firstname.lastname@example.org, phone: +46 8 442 58 50
Ketil Widerberg, CEO Oslo Cancer Cluster and Chairman of the Board Oslo Cancer Cluster Incubator, email: email@example.com, phone: +47 915 77 990
HealthCap is a leading European venture capital firm investing exclusively and globally in life sciences. A cornerstone of the strategy is to invest in companies developing therapeutic interventions that have the potential to significantly improve patient outcomes. HealthCap backs companies developing targeted therapies for rare diseases, orphan drugs, cancer and genetic diseases, among others. The HealthCap team of ten partners, five of whom are MD PhDs, has established its reputation as one of Europe’s preeminent life science specialists amongst VCs and entrepreneurs. See more at: www.healthcap.eu
Oslo Cancer Cluster
Oslo Cancer Cluster is a strong biotech cluster well positioned in the global oncology industry. The cluster is particularly strong in immuno-oncology and works to release the potential that lies within Norwegian oncology registries and bio banks. 70 members make up the cluster and represent the entire oncology value chain. www.oslocancercluster.no
Oslo Cancer Cluster Incubator
Oslo Cancer Cluster Incubator offers lab and office space to researchers and biotechs developing cancer treatments, as well as companies offering competence, services and an international network crucial to succeed in this globally competitive area. The incubator´s over all aim is to develop more companies based on excellent cancer research as well as to contribute to their success. Today, more than X companies are part of the incubator. www.occincubator.com
Oslo Cancer Cluster Innovation Park AS
Total space: 36 000 m²
Vision: The vision of the Oslo Cancer Cluster Innovation Park is to create Europe’s leading environment for education, research and industry within oncology, while also shortening the time it takes to develop new cancer medication and diagnostics.
Tenants: Oslo University Hospital, The Institute for Cancer Genetics and Informatics, Norwegian Cancer Registry, Oslo Cancer Cluster SA, Oslo Cancer Cluster Incubator AS, The Norwegian Radium Hospital Research Foundation, The Oslo Hospital Pharmacy, Ullern High School and leading Norwegian biotech companies such as Ultimovacs and PCI Biotech.
Owners: OBOS, Industrifinans, Radium Hospital Foundation, Utstillingsplassen Eiendom, Oslo Cancer Cluster and Oslo Cancer Cluster Incubator.
Opened officially August 24 2015 by the Prime Minister of Norway, Erna Solberg.